



## Early View

Original article

### **Exhaled Volatile Organic Compounds as Markers for Medication Use in Asthma**

Paul Brinkman, Waqar M. Ahmed, Cristina Gómez, Hugo H. Knobel, Hans Weda, Teunis J. Vink, Tamara M. Nijsen, Craig E. Wheelock, Sven-Erik Dahlen, Paolo Montuschi, Richard G. Knowles, Susanne J. Vijverberg, Anke H. Maitland-van der Zee, Peter J. Sterk, Stephen J. Fowler

Please cite this article as: Brinkman P, Ahmed WM, Gómez C, *et al.* Exhaled Volatile Organic Compounds as Markers for Medication Use in Asthma. *Eur Respir J* 2019; in press (<https://doi.org/10.1183/13993003.00544-2019>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

REVISION

The European Respiratory Journal - ERJ-00544-2019

Title page

**Exhaled Volatile Organic Compounds as Markers for Medication Use in Asthma**

Paul Brinkman<sup>1</sup>, Waqar M. Ahmed<sup>2</sup>, Cristina Gómez<sup>3,4</sup>, Hugo H. Knobel<sup>5</sup>, Hans Weda<sup>6</sup>, Teunis J. Vink<sup>6</sup>, Tamara M. Nijsen<sup>6</sup>, Craig E. Wheelock<sup>4</sup>, Sven-Erik Dahlen<sup>3</sup>, Paolo Montuschi<sup>7</sup>, Richard G. Knowles<sup>8</sup>, Susanne J. Vijverberg<sup>1</sup>, Anke H. Maitland-van der Zee<sup>1</sup>, Peter J. Sterk<sup>1</sup>, Stephen J. Fowler<sup>2,9</sup> on behalf of the U-BIOPRED Study Group<sup>10</sup>.

<sup>1</sup> Amsterdam UMC, University of Amsterdam, Department of Respiratory Medicine, Meibergdreef 9, Amsterdam Netherlands.

<sup>2</sup> Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom

<sup>3</sup> Institute of Environmental Medicine and the Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.

<sup>4</sup> Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

<sup>5</sup> Philips Signify, Eindhoven, The Netherlands

<sup>6</sup> Philips Research, Eindhoven, The Netherlands

<sup>7</sup> Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart,  
Rome, Italy

<sup>8</sup> Knowles Consulting, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage SG1  
2FX, United Kingdom

<sup>9</sup> Manchester Academic Health Science Centre, Manchester University Hospitals NHS  
Foundation Trust, United Kingdom

<sup>10</sup> See supplementary U-BIOPRED Study Group Contributors list

Corresponding author:

P. Brinkman, MSc

Department of Respiratory Medicine, F5-259

Amsterdam UMC, University of Amsterdam

Meibergdreef 9

1105 AZ Amsterdam

The Netherlands

Telephone: +31 (0) 20 56 66072

Fax: +31 (0) 20 56 69001

[p.brinkman@amc.uva.nl](mailto:p.brinkman@amc.uva.nl)

## ABSTRACT

### Rationale

Asthma is a heterogeneous condition, characterized by chronic inflammation of the airways, typically managed with inhaled bronchodilators and corticosteroids. In case of uncontrolled asthma, oral corticosteroids (OCSs) are often prescribed. Good adherence and inhalation technique are associated with improved outcomes, however it is difficult to monitor appropriate drug intake and effectiveness in individual patients. Exhaled breath contains thousands of volatile organic compounds (VOCs) that reflect changes in the body's chemistry, and may be useful for monitoring drug pharmacokinetics and pharmacodynamics. We aimed to investigate the association of exhaled VOCs in severe asthma patients from the U-BIOPRED cohort (by gas chromatography-time-of-flight-mass spectrometry) with urinary levels of salbutamol and oral corticosteroids (OCS) (by liquid chromatography-high resolution mass spectrometry).

### Methods

Samples were collected at baseline and after 12-18 months of follow-up. Statistical analysis was based on univariate and multivariate modeling, followed by area under the receiver operating characteristics (AUROC) calculation. Results were verified through longitudinal replication and independent validation.

### Results

Data were available for 78 patients (baseline: n=48; replication: n=30; validation: n=30). Baseline AUROCs (95% CI) were 82.1 (70.4-93.9) for salbutamol and 78.8 (65.8-91.8) for OCS. These outcomes could adequately be replicated and validated. Additional regression analysis between qualified exhaled VOCs and urinary concentrations of salbutamol and prednisone, showed statistically significant correlations ( $p < 0.01$ ).

## Conclusion

In summary, we have linked exhaled VOCs to urinary detection of salbutamol and OCS. This merits further development of breathomics into a point of care tool for therapeutic drug monitoring.

## INTRODUCTION

Asthma is a heterogeneous disease, characterized by variable airflow obstruction and chronic inflammation of the airways. Control of asthma in general is managed with inhaled bronchodilator therapy and inhaled corticosteroids (ICS). In uncontrolled asthma and acute exacerbations short courses of oral corticosteroids (OCS) are often prescribed, whilst in patients with severe disease maintenance therapy with OCS can be required [1]. Good adherence and adequate inhalation technique are associated with improved outcomes, however it is difficult for clinicians to monitor appropriate medication intake and drug effectiveness in individual patients [2, 3].

Besides pulmonologists, the World Anti-Doping Agency (WADA) and the International Olympic Committee (IOC) are interested in monitoring asthma treatments because of ergogenic effects. Although most bronchodilators and steroids are prohibited in-competition and require a Therapeutic Use Exemption (TUE), usage of both drugs is still under debate. An important element of this discussion is the significant variability among individuals in the metabolism of the drugs [4-6]. Therefore, techniques suitable for monitoring these drugs in both athletes and patients are needed.

Exhaled breath contains thousands of volatile organic compounds (VOCs) that reflect changes in the body's chemical metabolism, since they are by-products of metabolic and pathological processes at cellular and tissue levels. Metabolomic analysis of expired VOCs (breathomics) is commonly based on analytical methods such as gas chromatography and mass spectrometry (GC-MS) and/or cross-reactive gas-sensor electronic nose (eNose) technology and is suggested to be used for: 1) diagnosis of disease, 2) disease phenotyping,

3) prediction of exacerbations and 4) prediction of treatment response [7-11]. Furthermore it has been shown that some exhaled VOCs exhibit characteristic behavior shortly after the onset of exercise [12].

Since our lungs are in direct contact with the blood circulation, the analysis of exhaled volatiles may also be employed to monitor uptake and distribution of drugs [13, 14]. As breath sampling is non-invasive, (virtually) inexhaustible and, for the purposes of the Human Tissue Act, constitutes a “non-biological material”, it potentially is a preferable source to detect biological responses and metabolism kinetics of drugs than blood and urine. Despite all this, the analysis of exhaled VOCs for pharmacokinetic purposes has thus far received limited attention [13, 14]

Given that breathomics has real potential in the field of pharmacokinetics, we hypothesized that there is an association between markers of recent drug usage in urine, as current gold standard, and exhaled VOCs. We therefore aimed to detect asthma medications in urine of severe asthma patients from the U-BIOPRED project [15] by liquid chromatography–mass spectrometry (LC-MS) and to link those to exhaled VOCs or breath profiles measured by GC-MS.

## METHODS

*Participants.* In this study, data from an unselected subset of adult subjects (aged  $\geq 18$  years) participating in the pan-European U-BIOPRED cohort study were included [15]. All participants were diagnosed with severe asthma according IMI-criteria [16]. In short, patients were prescribed high dose ICS [at least 1000  $\mu\text{g}$  per day fluticasone propionate (FP) or equivalent] plus at least one other controller medication and were defined uncontrolled according to Global Initiative for Asthma (GINA) guidelines and/or had at least two severe exacerbations in the preceding year and/or required prescription of daily oral OCS (maintenance) to achieve asthma control. Potential participants were excluded if they had an exacerbation in the previous month prior to enrollment. The study was approved by all local medical ethics committees and all patients gave written informed consent. The study was registered at ClinicalTrials.gov identifier: NCT01976767.

*Design.* The U-BIOPRED study in adults comprised three visits as reported in detail elsewhere [15]. At the first visit participants were screened for eligibility to participate according to the inclusion and exclusion criteria. Of relevance to the present study several measurements were performed. In rank of order according to study protocol, the assessments during baseline visit (second visit) and at 12-18 months follow-up visit (third visit) were: urine sampling and completion of questionnaires, followed by pre- and post-bronchodilator spirometry testing. Next, fractional exhaled nitric oxide ( $\text{F}_{\text{ENO}}$ ) was measured and exhaled breath collected, which was within 60 minutes from urine sampling. Finally, blood was drawn and allergy tests were carried out, all as outlined previously [15]. All baseline measurements were defined as training set, while 12-18 months follow-up samples were split into replication (revisits) and a validation (previously unsampled patients) sets.



## Methods of measurement

*Exhaled breath collection and analysis.* Exhaled breath was collected at eight participating sites using a previously described method [9, 10]. In short, patients breathed for 5 min at tidal volume through a two-way non-rebreathing valve and an organic compound filter (A2, North Safety, Middelburg, Netherlands). Next, the subject exhaled a single vital capacity volume into a 10 L Tedlar bag (SKC Inc, Eighty Four, PA, USA). The exhaled VOCs were then trapped on sorbent tubes containing Tenax (Tenax GR SS 6mm x 7", Gerstel, Mülheim an der Ruhr, Germany), by pulling the air through the Tenax tube using a peristaltic pump at a flow rate of 250 ml/min. Such storage of VOCs preserves the exhaled marker signal [17].

At the Philips research lab (Philips research, Eindhoven, The Netherlands), Tenax tubes were thermally desorbed (Gerstel TDS, Mülheim an der Ruhr, Germany) using helium as carrier gas. The sample was transmitted to a packed liner, heated to 300°C for 3 min and subsequently transferred to a Tenax TA cold trap (at -150°C), which was heated after 2 min to 280°C at 20°C/s and splitless injected onto the chromatographic column. Compounds were separated using capillary gas-chromatography with helium as a carrier gas at 1.2 mL/min (7890 N GC, Agilent, Santa Clara, CA, USA) on a VF1-MS column (30 m × 0.25 mm, film thickness 1 µm, 100% dimethylpolysiloxane, Varian Chrompack, Middelburg, The Netherlands). The temperature of the gas chromatograph was adjusted in three steps: 40°C for 5 min, increased until 300°C with 10°C/min, and finally held isothermally for 5 min. A Time-of-Flight mass spectrometer (LECO Pegasus 4D, LECO, Sint Joseph, MI, USA), in electron ionization mode at 70eV, was used for the detection of product ions (ranging from 29 to 400 Da).

*Urine collection and analysis.* Before the visit, patients were asked not to take food and drinks that were diuretic. The urine sample was split into five 8 mL tubes (Sarstedt AG & Co, Nümbrecht, Germany). The capped tubes were immediately stored in vertical position in a freezer (-20°C).

All urine samples were analyzed at the department of Medical Biochemistry and Biophysics of the Karolinska Institutet (Karolinska Institutet, Stockholm, Sweden). The sample preparation for determining fragments or metabolites of salbutamol and corticosteroids was performed on a robotic liquid-handling platform (Microlab STAR, Hamilton Robotics, Bonaduz, Switzerland). The corticosteroids and the salbutamol were prepared from an aliquot of urine fortified with internal standards and subsequently hydrolyzed using  $\beta$ -glucuronidase (E-coli). Purification was performed using mixed mode solid phase extraction (SPE) in 96 well plate format. The analysis of the extract was performed with reversed phase liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS, Thermo Q-Exactive, Thermo Fisher Scientific Inc, Waltham, USA). Acquisition of raw LC-HRMS data was performed in full scan mode at a resolution of 35000 with polarity switching.

As a next step two summarizing, dichotomous variables were established regarding the observation of salbutamol and corticosteroid residues in a sample. Presence of corticosteroids was determined based on the remains of prednisone and/or prednisolone and/or methylprednisolone and/or 16 $\alpha$ -hydroxy-prednisolone and/or 20 $\beta$ -dihydro-prednisolone [18, 19]. These two outcomes were used to split the patients into groups (salbutamol detected: yes/no and corticosteroids detected: yes/no) for statistical analysis. The limit of detection (LoD) for all these compounds was 1 ng/mL [20], with an expected terminal half-life of 4-6 hours for salbutamol and 2-4 hours for prednisolone [21].

*Lung function.* Spirometry was executed before and 10 minutes after intake of 400 µg of salbutamol via a spacer according to ERS recommendations using daily-calibrated lung function equipment [22].

*Blood.* Blood eosinophils and neutrophils percentages were obtained from standard complete blood counts.

*Allergic status.* Allergy testing was performed using total and specific serum IgE and skin prick test (SPT) to a panel of common aeroallergens. Atopy was defined as the presence of sensitization on SPT (wheal  $\geq$  3 mm) or serum specific IgE ( $\geq$  0.35 kU/L)

*FE<sub>NO</sub>.* Fractional exhaled lower respiratory nitric oxide was measured with a portable device (NIOX Mino System; Aerocrine, Solna, Sweden) at a constant flow rate of 50 mL/s, according to ATS/ERS recommendations [23].

## Analysis

*Data cleaning and reduction.* As a first step in preprocessing, raw GC-MS files were converted into netCDF files, subsequently peak alignment was realized using XCMS [24]. After ComBat batch correction [25] on the complete dataset of both baseline and 12-18 months follow-up samples, GC-MS data was divided into a training, replication and validation set. Subsequently, datasets were normalized by adjusting the average and standard deviation of each individual GC-MS fragment to respectively 0 and 1.

*Univariate analysis.* To select potentially relevant VOCs for the distinction between the drugs-detected *versus* no-drugs-detected groups, we applied a strategy reported by van Oort *et al* [26]. This applies Wilcoxon sum-rank testing combined with computation of area under

the receiver operating characteristics (AUROC) for each GC-MS fragment. Features with a p-value  $< 0.05$  and an AUROC  $\geq 0.7$  were retained for further analysis. After filtering for multicollinearity through correlation analysis ( $r \geq 0.95$ ), spectra of GC-MS features retained after univariate analysis were provisionally identified based on NIST-library (v.2014) matching. Compounds determined as instrument artefacts i.e. silanes and siloxanes [27], or Tedlar bag related substances [28] were considered as contaminants and removed for further analysis.

*Multivariate analysis.* A sparse partial least square (SPLS) analysis [29] was utilized on persevered GC-MS fragments in order to reveal most optimal set of features for discrimination between groups of interest. Optimal modeling settings for *eta* (thresholding parameter) and K (number of hidden components) were objectively defined by the algorithms with 10-fold cross validation. Next a composite score of the final set of selected variables was calculated via a leave-one-out linear discriminant analysis. The diagnostic performance of the (breath based) discriminant score *versus* urine LC-MS outcomes (drugs-detected or no-drugs-detected) was tested by calculation of the AUROC combined with 95% confidence interval (CI).

*Validation.* Baseline outcomes were validated by rerunning final two steps of analysis, linear discriminant score and AUROC calculation on two datasets: follow-up samples of baseline patients (*replication*) and an independent group of follow-up patients lacking paired (breath and urine) baseline samples (*validation*).

*Correlation analysis.* Finally the association between univariate preserved features and urinary concentrations of salbutamol, prednisone and prednisolone were determined on all samples (baseline + follow-up) together. After SPLS modeling, bootstrapped linear regression analysis (1000 replicates) was applied to test robustness of the models.

All analyses were performed in RStudio (v.1.0.136; RStudio Team (2016). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA; <http://www.rstudio.com>) using R (v.3.3.3; R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; <https://www.R-project.org>) as engine and supported by R packages: XCMS, data.table, MASS, pROC, caret, spls, sva.

## RESULTS

Complete data on both breath and urine were available for 48 baseline and 60 follow-up visits, occurring at eight research sites across five countries in Europe. Patient characteristics are summarized in Table 1. A flowchart on patient enrolment is shown in Figure 4

There was no complete overlap between the patients from who baseline and follow-up data was available. During the follow-up visits at 12-18 months, 30 patients were measured for the second time (called the “replication” set) and 30 patients for the first time (called the “validation” set). Of patients within the replication set, a few had changed medication regime after the baseline visit. Four of them were withdrawn from OCS, another four were prescribed an increased OCS dose and one patient was withdrawn from long-acting  $\beta$ 2-agonists usage.

*Univariate analysis.* Analysis of the 48 baseline breath samples resulted in the detection of 7115 ion fragments. After preprocessing and combining outcomes of both Wilcoxon sum-rank ( $p < 0.05$ ) and AUROC (AUC > 0.7) test, the number of discriminatory features for GC-MS breathomics in regard to traces of salbutamol and OCS in urine (yes/no) by LC-MS, were respectively 79 and 28. Out of these 107 fragments, 48 were excluded either due to multicollinearity ( $n = 26$ ), or were considered to represent either contaminants ( $n = 13$ ) or internal standards ( $n = 9$ ), which resulted in 49 ‘salbutamol’ and 10 ‘OCS’ related fragments.

*Multivariate analysis.* After SPLS modeling, seven discriminatory compounds remained for salbutamol and four for OCS [Table 2].

The subsequent linear discriminant score calculation resulted in final baseline AUROCs of 82.1 (95%CI: 70.4-93.9) % for GC-MS breath vs. LC-MS urine (salbutamol detected: yes/no) and 78.8 (95%CI: 65.8-91.8) % for GC-MS breath vs. LC-MS urine (OCS detected: yes/no). These outcomes were replicated and validated using the two longitudinal datasets, resulting in outcomes for salbutamol of: replication 67.0 (95%CI: 46.0-88.0) % and validation 90.9 (95%CI: 78.9-100.0) % and for OCS: replication 70.1 (95%CI: 50.8-89.5) % plus validation: 82.1 (95%CI: 67.2-97.1) % [Table 2 + Figure 1 + Figure 2].

*Association with urinary levels of salbutamol and OCS.* SPLS modeling followed by regression analysis among classifying GC-MS features and urinary concentrations of salbutamol, prednisone and prednisolone, resulted in three linear models with  $R^2$  of respectively: 0.10 (95%CI: 0.00-0.23) , 0.63 (95%CI: 0.33-0.94) and 0.29 (95%CI: 0.05-0.48), all  $p < 0.01$ . The most stable model (association with prednisone), was based on four compounds: lysine [retention time: 899.17 seconds], glycolic acid [retention time: 952.50 seconds], 4-carene [retention time: 1011.67 seconds] and octanal [retention time: 1046.48 seconds] [Table 3 & Figure 3].

## DISCUSSION

The present study examined the link between exhaled VOCs by GC-MS and traces of asthma medications in urine of severe asthma patients as measured by LC-MS. The distinction between the urine based drugs-detected vs. no-drugs-detected groups by the exhaled marker models resulted in moderate to good AUROCs of approximately 80% for both OCs and salbutamol. Both outcomes could be replicated (revisits) and validated (previously unsampled patients) using samples obtained during 12-18 months follow-up visits. Our results indicate that profiles of exhaled VOCs might be useful for monitoring drug levels. These outcomes should be extended towards time series analysis, which argues for pharmacokinetic pathway and dose ranging studies on asthma medication. Additionally, expanding to other types of asthma medication like ICS and long-acting  $\beta$ 2-agonists would strongly increase the added value of the proposed method of drug level monitoring.

To our knowledge, this is the first study examining exhaled VOCs in relationship with drug usage as detected by urinary metabolites in asthma. The novelty of the present study is represented by linking two sources of excretion, urine and exhaled VOCs regarding the metabolism of asthma medication. Previously breath profiles have been linked to the metabolic effects of inhaled salbutamol [30] and eucalyptol [31] during a controlled drug regimen. The present study takes an additional step by relating exhaled metabolomics to urinary traces of the drugs.

One of the strengths of this study is the availability of a longitudinal replication dataset and an independent validation cohort. Secondly, the analytical techniques for both urine and breath analysis were highly sophisticated and performed in experienced laboratories.



Thirdly, patient grouping regarding the usage of asthma medications was based on detection of urinary metabolites by LC-MS, which might be more accurate than patient self-reporting or prescriptions [32]. Finally this work arises from a pan-European study, with data originating from five different countries. Despite the multicenter and cross-border character of this study, which may have introduced variation within data, a link between urine and exhaled markers could be revealed. This may be a result of well documented standardized operating protocols and the application of a thoroughly tested breath collection technique [9, 10].

We realize that this study has several limitations. Firstly, due to the observational of this study the specific time and dose of medication intake, and levels of hydration and nutrition are uncertain. Which is emphasized by the relative poor agreement between prescription of maintenance oral corticosteroids and the urinary prednisolone positive patients within the training set. Additionally, there is a natural variability among individuals in the metabolism of the drugs [4, 5]. Despite those limitations, a link between systemic markers of drug uptake in urine and exhaled markers was revealed which could be replicated and validated. Furthermore, since adherence within this study was based on a direct urinary measurement, the time of dosing is less relevant. A second limitation is related to the correlation analysis between urine and breath, which could only include patients with traces of medication in their urine. As consequence of that, the number of samples were decreased in comparison to the first series of analyses of the study. This may have affected the robustness of the model, as represented by wide 95% confidence intervals. Therefore, the outcomes of our regression analysis should be cautiously interpreted. Finally, the results obtained within the replication group are lower than those of the training and validation set. Although we

couldn't find a direct cause for this, we assume that a minor (technical) variation, exhaled breath or urine related, among a few patients within the relatively small group ( $n=30$ ) affected the results. The adequate outcomes of the validation set, which builds upon the models of the trainings set too, strengthens such assumption.

How can we explain our findings? Out of eleven GC-MS features adopted in the two distinction models, two compounds are associated with downstream metabolic pathways. This concerns methyl-acetate for salbutamol and octanal for OCS, which are reported in the KEGG database as products of carbohydrate pyruvate metabolism [33] and an aldehyde product of lipid peroxidation [33], respectively. These outcomes fit earlier findings regarding changes in metabolic energy processes after intake of both drugs [30, 34, 35]. Regarding the compounds fostered in the presented regression analysis, lysine and glycolic acid are of interest. Lysine, an essential amino acid, might have a link to the activation of genes by corticosteroids [36], while glycolic acid shows a remarkable similarity with the  $\text{COCH}_2\text{OH}$ -tail of prednisone. From the remaining set of compounds included in the final models, butyrolactone and 4-carene are described as potential biomarkers for respectively lung- and breast cancer [37, 38], however to our best knowledge no direct link to asthma nor medication usage has been reported yet. Closely related to 4-carene in their chemical structure are 3-carene and 3-carane, interestingly these two VOCs have been associated with lung infections [39]. Despite possible usage as flavor additive (levomenthol and carvone) or a compound emitted by a microorganism (chlorobenzene) [40], no direct nor indirect link was found yet for the other reported compounds.

What are the clinical implications of our data? The current study presents an association between excreted traces of asthma medication in urine and exhaled breath metabolomics. Therefore, breath might be a more favorable source to analyze biological responses and pharmacokinetics of asthma drugs than blood and urine, especially since it is non-invasive and practically inexhaustible. It suggests the advancement of current outcomes towards a breathomics based, quick and non-invasive point of care tool for pharmacokinetic monitoring purposes or adherence testing, as are currently undertaken for the diagnosis of asthma, COPD and lung cancer using gas-sensor driven electronic nose (eNose) technology. [11]. In addition, breathomics may qualify for rapid and frequent sampling of asthma drug use in sport science, for example testing misuse of drugs by athletes at real-time.

In conclusion, metabolomics of exhaled breath is associated with markers of recent drug usage in urine. This suggests that breathomics qualifies for development into a point-of-care tool for monitoring drug level changes in both patients and athletes.

## ACKNOWLEDGEMENTS

This paper is presented on behalf of the U-BIOPRED Study Group. The authors would like to thank patients and their families for their participation.

## FUNDING

U-BIOPRED has received funding from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in-kind contribution ([www.imi.europa.eu](http://www.imi.europa.eu)).

## CONFLICT OF INTEREST/DISCLOSURE

Disclosure of potential conflict of interest: PB, CEW, SED, PM, PJS and SJF received grant support from Innovative Medicines Initiative. RGK consults through Knowles Consulting Ltd for a variety of companies and Universities, and particularly for Peptinnovate Ltd as CSO. AHM reports grants from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline and Novartis outside the submitted work. WMA, CG, HHK, HW, TJV, TMN and SJV have no relevant conflict no interest to disclose.

## AUTHORS CONTRIBUTIONS

PB; Study design, dry lab analysis and wrote the manuscript. WMA; Dry lab analysis and amended the manuscript. CG; Wet and dry lab analysis (LC-MS). HHK; Wet lab analysis (GC-MS). HW; Dry lab analysis (GC-MS). TJV; Contributed to GC-MS analysis. TMN; Contributed to GC-MS analysis. CEW; Contributed to LC-MS analysis. SED; Contributed to LC-MS analysis. PM; Contributed to sample collection. RGK; Contributed to study design. SJV; Amended the

manuscript. AHM; Amended the manuscript. PJS; Study design and amended the manuscript. SJF; Study design and wrote the manuscript.

## REFERENCES

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2017 [cited; Available from: <http://ginasthma.org/>]
2. Mokoka MC, Lombard L, MacHale EM, Walsh J, Cushen B, Sulaiman I, Carthy DM, Boland F, Doyle F, Hunt E, Murphy DM, Faul J, Butler M, Hetherington K, Mark FitzGerald J, Boven JFV, Heaney LG, Reilly RB, Costello RW. In patients with severe uncontrolled asthma, does knowledge of adherence and inhaler technique using electronic monitoring improve clinical decision making? A protocol for a randomised controlled trial. *BMJ open* 2017; 7(6): e015367.
3. Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P, Green RH. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. *Thorax* 2012; 67(8): 751-753.
4. Fitch KD. The enigma of inhaled salbutamol and sport: unresolved after 45 years. *Drug testing and analysis* 2017.
5. Zorgati H, Prieur F, Vergniaud T, Cottin F, Do MC, Labsy Z, Amarantini D, Gagey O, Lasne F, Collomp K. Ergogenic and metabolic effects of oral glucocorticoid intake during repeated bouts of high-intensity exercise. *Steroids* 2014; 86: 10-15.
6. World Anti Doping Agency. Medical Information to Support the Decisions of TUECs - Asthma 2017.
7. Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, Fowler SJ. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. *Thorax* 2011; 66(9): 804-809.
8. Fowler SJ, Basanta-Sanchez M, Xu Y, Goodacre R, Dark PM. Surveillance for lower airway pathogens in mechanically ventilated patients by metabolomic analysis of exhaled breath: a case-control study. *Thorax* 2015; 70(4): 320-325.
9. Dragonieri S, Schot R, Mertens BJ, Le Cessie S, Gauw SA, Spanevello A, Resta O, Willard NP, Vink TJ, Rabe KF, Bel EH, Sterk PJ. An electronic nose in the discrimination of patients with asthma and controls. *The Journal of allergy and clinical immunology* 2007; 120(4): 856-862.
10. Hekking PP, Loza MJ, Pavlidis S, de Meulder B, Lefaudeux D, Baribaud F, Auffray C, Wagener AH, Brinkman PI, Lutter RI, Bansal AT, Sousa AR, Bates SA, Pandis Y, Fleming LJ, Shaw DE, Fowler SJ, Guo Y, Meiser A, Sun K, Corfield J, Howarth PH, Bel EH, Adcock IM, Chung KF, Djukanovic R, Sterk PJ. Pathway discovery using transcriptomic profiles in adult-onset severe asthma. *The Journal of allergy and clinical immunology* 2017.
11. de Vries R, Dagelet YWF, Spoor P, Snoey E, Jak PMC, Brinkman P, Dijkers E, Bootsma SK, Elskamp F, de Jongh FHC, Haarman EG, In 't Veen J, Maitland-van der Zee AH, Sterk PJ. Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label. *The European respiratory journal* 2018; 51(1).
12. King J, Mochalski P, Kupferthaler A, Unterkofler K, Koc H, Filipiak W, Teschl S, Hinterhuber H, Amann A. Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study. *Physiological measurement* 2010; 31(9): 1169-1184.
13. Beauchamp J. Inhaled today, not gone tomorrow: pharmacokinetics and environmental exposure of volatiles in exhaled breath. *Journal of breath research* 2011; 5(3): 037103.
14. Pleil JD. Breath biomarkers in toxicology. *Archives of toxicology* 2016; 90(11): 2669-2682.
15. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, Pandis I, Bansal AT, Bel EH, Auffray C, Compton CH, Bisgaard H, Bucchioni E, Caruso M, Chanez P, Dahlen B, Dahlen SE, Dyson K, Frey U, Geiser T, Gerhardsson de Verdier M, Gibeon D, Guo YK, Hashimoto S, Hedlin G, Jeyasingham E, Hekking PP, Higenbottam T, Horvath I, Knox AJ, Krug N, Erpenbeck VJ, Larsson LX, Lazarinis N, Matthews JG, Middelvelde R, Montuschi P, Musial J, Myles D, Pahu L, Sandstrom T, Seibold W, Singer F, Strandberg K, Vestbo J, Vissing N, von Garnier C, Adcock IM, Wagers S, Rowe A, Howarth P, Wagener AH, Djukanovic R, Sterk PJ, Chung KF. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. *The European respiratory journal* 2015; 46(5): 1308-1321.

16. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). *Thorax* 2011; 66(10): 910-917.
17. van der Schee MP, Fens N, Brinkman P, Bos LD, Angelo MD, Nijssen TM, Raabe R, Knobel HH, Vink TJ, Sterk PJ. Effect of transportation and storage using sorbent tubes of exhaled breath samples on diagnostic accuracy of electronic nose analysis. *Journal of breath research* 2013; 7(1): 016002.
18. Matabosch X, Pozo OJ, Pérez-Mañá C, Farré M, Marcos J, Segura J, Ventura R. Identification of budesonide metabolites in human urine after oral administration. *Analytical and bioanalytical chemistry* 2012; 404(2): 325-340.
19. Matabosch X, Pozo OJ, Perez-Mana C, Papaseit E, Segura J, Ventura R. Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS. *Journal of mass spectrometry : JMS* 2015; 50(3): 633-642.
20. Mullen JE, Thorngren JO, Schulze JJ, Ericsson M, Garevik N, Lehtihet M, Ekstrom L. Urinary steroid profile in females - the impact of menstrual cycle and emergency contraceptives. *Drug testing and analysis* 2017; 9(7): 1034-1042.
21. Zorginstituut Nederland. Farmacotherapeutisch Kompas. 2018 [cited; Available from: <https://farmacotherapeutischkompas.nl>]
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. *The European respiratory journal* 2005; 26(2): 319-338.
23. American Thoracic S, European Respiratory S. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *American journal of respiratory and critical care medicine* 2005; 171(8): 912-930.
24. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. *Analytical chemistry* 2006; 78(3): 779-787.
25. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics (Oxford, England)* 2007; 8(1): 118-127.
26. van Oort PMP, de Bruin S, Weda H, Knobel HH, Schultz MJ, Bos LD, On Behalf of the MC. Exhaled Breath Metabolomics for the Diagnosis of Pneumonia in Intubated and Mechanically-Ventilated Intensive Care Unit (ICU)-Patients. *International Journal of Molecular Sciences* 2017; 18(2): 449.
27. McMaster MC. Appendix C: Sources of GC/MS Background Contamination. GC/MS. John Wiley & Sons, Inc., 2007; pp. 165-166.
28. Beauchamp J, Herbig J, Gutmann R, Hansel A. On the use of Tedlar(R) bags for breath-gas sampling and analysis. *Journal of breath research* 2008; 2(4): 046001.
29. Chung D, Keles S. Sparse Partial Least Squares Classification for High Dimensional Data. *Statistical Applications in Genetics and Molecular Biology* 2010; 9.
30. Gaugg MT, Engler A, Nussbaumer-Ochsner Y, Bregy L, Stoberl AS, Gaisl T, Bruderer T, Zenobi R, Kohler M, Martinez-Lozano Sinues P. Metabolic effects of inhaled salbutamol determined by exhaled breath analysis. *Journal of breath research* 2017; 11(4): 046004.
31. Beauchamp J, Kirsch F, Buettner A. Real-time breath gas analysis for pharmacokinetics: monitoring exhaled breath by on-line proton-transfer-reaction mass spectrometry after ingestion of eucalyptol-containing capsules. *Journal of breath research* 2010; 4(2): 026006.
32. Lim KG, Rank MA, Li JT, Patel A, Volcheck GW, Branda ME, Cabanela R, Naessens JM, Shah ND, Wagie A, Beebe T. How well does patient self-report predict asthma medication possession? Implications for medication reconciliation and adherence assessment. *The Journal of asthma : official journal of the Association for the Care of Asthma* 2010; 47(8): 878-882.
33. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic acids research* 2017; 45(D1): D353-d361.

34. Fowler SJ, Lipworth BJ. Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol. *British journal of clinical pharmacology* 2001; 51(4): 359-362.
35. Radhakutty A, Mangelsdorf BL, Drake SM, Samocha-Bonet D, Heilbronn LK, Smith MD, Thompson CH, Burt MG. Effects of prednisolone on energy and fat metabolism in patients with rheumatoid arthritis: tissue-specific insulin resistance with commonly used prednisolone doses. *Clinical endocrinology* 2016; 85(5): 741-747.
36. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? *Annals of internal medicine* 2003; 139(5 Pt 1): 359-370.
37. Ulanowska A, Kowalkowski T, Trawinska E, Buszewski B. The application of statistical methods using VOCs to identify patients with lung cancer. *Journal of breath research* 2011; 5(4): 046008.
38. Silva CL, Passos M, Camara JS. Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis. *Talanta* 2012; 89: 360-368.
39. Ahmed WM, Lawal O, Nijsen TM, Goodacre R, Fowler SJ. Exhaled Volatile Organic Compounds of Infection: A Systematic Review. *ACS Infectious Diseases* 2017; 3(10): 695-710.
40. Garbeva P, Hordijk C, Gerards S, de Boer W. Volatiles produced by the mycophagous soil bacterium *Collimonas*. *FEMS microbiology ecology* 2014; 87(3): 639-649.



## TABLES

Table 1: Demographic data and baseline characteristics of study population

	Training	Replication	Validation	p-value
Subjects; <i>n</i>	48	30	30	
Age; years [mean ± SD]	52.3 ± 14.1	54.9 ± 11.9	56.2 ± 10.1	0.38
Gender; female [%]	52.1	50.0	60.0	0.71
Body Mass Index (kg/m <sup>2</sup> ) [mean ± SD]	30.5 ± 5.8	30.7 ± 5.6	28.7 ± 6.3	0.32
Smoking status; current / ex- / non-smoker [%]	2.1 / 43.8 / 54.2	3.3 / 43.3 / 53.3	16.7 / 33.3 / 50.0	0.12
Pack years [median   IQR]	10.0   4.1 - 16.5	8.5   4.1 - 14.4	21.0   11.0 - 35.0	0.02
ICS(-LABA) prescription [%]	100	100	100	NA
OCS prescription [%]	64.6	56.7	56.7	0.71
Total daily OCS dose [median   IQR]	10.0   9.4 - 15.0	10.0   7.5 - 15.0	10.0   5.0 - 20.0	0.95
Short Acting β-Agonist prescription [%]	56.3	53.3	56.7	0.96
Long Acting β-Agonist prescription [%]	37.5	40.0	33.3	0.86
Leukotriene Modifiers prescription [%]	47.9	36.7	40.0	0.59
Anti-IgE therapy prescription [%]	20.8	23.3	16.7	0.81
Urinary prednisolone positive [%]	47.9	56.7	53.3	0.74
Urinary salbutamol positive [%]	29.2	43.3	20.0	0.14
Exacerbations/year [median   IQR]	1.00   1.00 - 2.25	1.50   0.00 - 2.75	1.00   0.00 - 2.75	0.60
Atopy positive [%]	66.7	63.3	66.7	0.95
ACQ; Juniper [median   IQR]	1.86   1.43 - 3.00	1.64   1.29 - 2.86	2.00   1.18 - 3.18	0.85
PbFEV <sub>1</sub> % predicted [mean ± SD]	76.8 ± 23.7	80.8 ± 21.6	75.4 ± 24.7	0.65
PbFEV <sub>1</sub> /FVC actual ratio [mean ± SD]	77.7 ± 18.9	76.0 ± 15.6	78.4 ± 19.8	0.87
F <sub>ENO</sub> ; ppb [median   IQR]	33.5   20.0 - 53.0	37.8   19.6 - 55.3	18.5   13.5 - 27.5	<0.01
Blood eosinophils; 10 <sup>9</sup> /L [median   IQR]	0.17   0.10 - 0.37	0.18   0.60 - 0.43	0.20   0.09 - 0.40	0.99
Blood neutrophils; 10 <sup>9</sup> /L [median   IQR]	5.31   4.08 - 8.01	6.27   4.79 - 7.67	6.24   4.85 - 7.61	0.60

OCS prescription, require prescription of daily or alternate day oral corticosteroids; Total daily OCS dose, daily OCS dose normalized to prednisolone, amongst OCS users; Short Acting β-Agonist prescription, require prescription of daily short acting β-Agonists; Long Acting β-Agonist prescription, require prescription of daily long acting β-Agonists; Leukotriene modifiers prescription, require prescription of daily leukotriene modifiers; Anti-IgE therapy prescription, require prescription of anti-IgE therapy at weekly or monthly basis. Urinary prednisolone positive, prednisolone traces in urine detected by LC-HRMS; Urinary salbutamol positive, salbutamol traces in urine detected by LC-HRMS; Atopy, presence of sensitization on SPT (wheal ≥ 3mm) or serum specific IgE (≥ 0.35 kU/L); ACQ, Juniper - Asthma Control Questionnaire; PbFEV<sub>1</sub>, Post-bronchodilator Forced Expiratory Volume in one second; FVC, Forced Vital Capacity; F<sub>ENO</sub>, Fraction of Exhaled Nitric Oxide in parts per billion. Differences between groups were tested using ANOVA (parametric) or Kruskal-Wallis (non-parametric) testing for continuous data and the Pearson's Chi-squared tests for categorical data.

Table 2: Adopted GC-TOF-MS features into the two (salbutamol detected: yes/no and corticosteroids detected: yes/no) distinction models after SPLS modeling.

Compound name	Ret.time (sec)	salbutamol	oral corticosteroids
Methyl acetate	498.90	X	
1-propanol	527.37	X	
Butanal	561.85	X	
Methyl propionate	611.23	X	
3-methyl-Butanal	639.07	X	
Chloro-benzene	896.80		X
Butyrolactone	929.10	X	
Glycolic acid	952.50		X
Octanal	1046.48		X
Levomenthol	1236.51		X
Carvone	1301.60	X	

Compound name, most probable compound based on NIST-library; Ret.time, retention time of fragment in seconds; salbutamol, fragments retaining after SPLS modeling of on traces of salbutamol in urine; oral corticosteroids, fragments retaining after SPLS modeling on traces of oral corticosteroids in urine.

Table 3: GC-TOF-MS features adopted into the SPLS based model used for the bootstrapped linear regression analysis between exhaled markers and concentrations of prednisone in urine.

Compound name	Ret.time
Lysine	899.17
Glycolic acid	952.50
4-Carene	1011.67
Octanal	1046.48

Compound name, most probable compound based on NIST-library; Ret.time, retention time of fragment in seconds.




Figure 1: AUROC's: GC-MS breath profiles vs. LC-MS urine (salbutamol detected YES/NO), on baseline and validation dataset. Baseline: 82.1 (95%CI: 70.4-93.9), replication: 67.0 (95%CI: 46.0-88.0%) and validation: 90.9 (95%CI: 78.9-100.0).




Figure 2: AUROC's: GC-MS breath profiles vs. LC-MS urine (OCS detected YES/NO), on baseline and validation dataset. Baseline: 78.8 (95%CI: 65.8-91.8), replication: 70.1 (95%CI 50.8-89.5) and validation: 82.1 (95%CI: 67.2-97.1).





Figure 3: Associations between exhaled marker based SPLS model vs. log transformed concentrations of prednisone in urine (ng/mL) by linear regression analysis ( $R^2=0.63$ ,  $95\%CI(0.33-0.94)$   $p<0.01$ ),  $n=15$ .



<sup>1</sup>cohort A: severe nonsmoking asthma (<5 pack years)

<sup>2</sup>cohort B: smokers and ex-smokers with severe asthma (>5 pack years)

<sup>3</sup>cohort C: mild/moderate nonsmoking asthmatics

<sup>4</sup>cohort D: healthy nonsmoking controls

<sup>5</sup>training set: all baseline samples of patients from cohort A & B

<sup>6</sup>replication set: all available 12-18 month revisit samples of patients included in the training set

<sup>7</sup>validation set: all available 12-18 month revisit samples of patients without a baseline sample

Figure 4: A flowchart of the patients enrolled in the study.



## U-BIOPRED

The U-BIOPRED consortium wishes to acknowledge the help and expertise of the following individuals and groups without whom, the study would not have been possible:

### Definition for the U-BIOPRED Study Group Supplementary authors

-----  
 Clinical site research leads  
 Platform leads  
 Data cleaning team  
 Data analysis team  
 Scientific Board and Management Board members  
 Core project management staff

### Definition for the U-BIOPRED Study Group Contributors list

Significant involvement in the clinical study

U-BIOPRED Supplementary authors	
Name	Affiliation
Adcock I M	National Heart and Lung Institute, Imperial College, London, UK;
Ahmed H	European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France;
Auffray C	European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France;
Bakke P	Department of Clinical Science, University of Bergen, Bergen, Norway;
Bansal A T	Acclarogen Ltd, St. John's Innovation Centre, Cambridge, UK;
Baribaud F	Janssen R&D, USA;
Bates S	Respiratory Therapeutic Unit, GSK, London, UK;
Bel E H	Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Bigler J	<i>Previously Amgen Inc</i>
Bisgaard H	COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
Boedigheimer M J	Amgen Inc.; Thousand Oaks, USA
Bønnelykke K	COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark;
Brandsma J	University of Southampton, Southampton, UK
Brinkman P	Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Bucchioni E	Chiesi Pharmaceuticals SPA, Parma, Italy
Burg D	Centre for Proteomic Research, Institute for Life Sciences, University of Southampton, Southampton, UK
Bush A	National Heart and Lung Institute, Imperial College, London, UK; Royal Brompton and Harefield NHS trust, UK
Caruso M	Dept. Clinical and Experimental Medicine, University of Catania, Catania, Italy;
Chaiboonchoe A	European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France;
Chanez P	Assistance publique des Hôpitaux de Marseille - Clinique des bronches, allergies et sommeil, Aix Marseille Université, Marseille, France
Chung F K	National Heart and Lung Institute, Imperial College, London, UK;
Compton C H	Respiratory Therapeutic Unit, GSK, London, UK
Corfield J	Areteva R&D, Nottingham, UK;





U-BIOPRED

D'Amico A	University of Rome 'Tor Vergata', Rome Italy;
Dahlén B	Karolinska University Hospital & Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Dahlén S E	Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
De Meulder B	European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France;
Djukanovic R	NIHR Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, Southampton, UK;
Erpenbeck V J	Translational Medicine, Respiratory Profiling, Novartis Institutes for Biomedical Research, Basel, Switzerland;
Erzen D	Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach, Germany
Fichtner K	Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach, Germany
Fitch N	BioSci Consulting, Maasmechelen, Belgium;
Fleming L J	National Heart and Lung Institute, Imperial College, London, UK; Royal Brompton and Harefield NHS trust, UK
Formaggio E	<i>Previously CROMSOURCE, Verona Italy</i>
Fowler S J	Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Frey U	University Children's Hospital, Basel, Switzerland;
Gahlemann M	Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland;
Geiser T	Department of Respiratory Medicine, University Hospital Bern, Switzerland;
Goss V	NIHR Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Sir Henry Wellcome Laboratories, Faculty of Medicine, University of Southampton, Southampton, UK;
Guo Y	Data Science Institute, Imperial College, London, UK;
Hashimoto S	Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Haughney J	International Primary Care Respiratory Group, Aberdeen, Scotland;
Hedlin G	Dept. Women's and Children's Health & Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden;
Hekking P W	Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Higenbottam T	Allergy Therapeutics, West Sussex, UK;
Hohlfeld J M	Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany
Holweg C	Respiratory and Allergy Diseases, Genentech, San Francisco, USA
Horváth I	Semmelweis University, Budapest, Hungary
Howarth P	NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK
James A J	Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden;
Knowles RG	Knowles Consulting Ltd, Stevenage. UK;
Knox A J	Respiratory Research Unit, University of Nottingham, Nottingham, UK;
Krug N	Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany;
Lefaudeaux D	European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France;
Loza M J	Janssen R&D, USA;



U-BIOPRED

Lutter R	Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Manta A	Roche Diagnostics GmbH, Mannheim, Germany
Masefield S	European Lung Foundation, Sheffield, UK;
Matthews J G	Respiratory and Allergy Diseases, Genentech, San Francisco, USA;
Mazein A	European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France
Meiser A	Data Science Institute, Imperial College, London, UK
Middelveld R J M	Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Miralpeix M	Almirall, Barcelona, Spain;
Montuschi P	Università Cattolica del Sacro Cuore, Milan, Italy;
Mores N	Università Cattolica del Sacro Cuore, Milan, Italy;
Murray C S	Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Musial J	Dept. of Medicine, Jagiellonian University Medical College, Krakow, Poland
Myles D	Respiratory Therapeutic Unit, GSK, London, UK;
Pahus L	Assistance publique des Hôpitaux de Marseille, Clinique des bronches, allergies et sommeil Espace Éthique Méditerranéen, Aix-Marseille Université, Marseille, France;
Pandis I	Data Science Institute, Imperial College, London, UK
Pavlidis S	National Heart and Lung Institute, Imperial College, London, UK
Postle A	University of Southampton, UK
Powel P	European Lung Foundation, Sheffield, UK;
Praticò G	CROMSOURCE, Verona, Italy
Puig Valls M	CROMSOURCE, Barcelona, Spain
Rao N	Janssen R&D, USA;
Riley J	Respiratory Therapeutic Unit, GSK, London, UK;
Roberts A	Asthma UK, London, UK;
Roberts G	NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK;
Rowe A	Janssen R&D, UK;
Sandström T	Dept of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden;
Schofield JPR	Centre for Proteomic Research, Institute for Life Sciences, University of Southampton, Southampton, UK
Seibold W	Boehringer Ingelheim Pharma GmbH, Biberach, Germany
Selby A	NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK;
Shaw D E	Respiratory Research Unit, University of Nottingham, UK;
Sigmund R	Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach, Germany
Singer F	University Children's Hospital, Zurich, Switzerland;
Skipp P J	Centre for Proteomic Research, Institute for Life Sciences, University of Southampton, Southampton, UK
Sousa A R	Respiratory Therapeutic Unit, GSK, London, UK;
Sterk P J	Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Sun K	Data Science Institute, Imperial College, London, UK
Thornton B	MSD, USA
van Aalderen W M	Academic Medical Centre, University of Amsterdam, Amsterdam,



	The Netherlands;
van Geest M	AstraZeneca, Mölndal, Sweden;
Vestbo J	Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Vissing N H	COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark;
Wagener A H	Academic Medical Center Amsterdam, Amsterdam, The Netherlands
Wagers S S	BioSci Consulting, Maasmechelen, Belgium
Weiszhart Z	Semmelweis University, Budapest, Hungary;
Wheelock C E	Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden;
Wilson S J	Histochemistry Research Unit, Faculty of Medicine, University of Southampton, Southampton, UK;

### Contributors

Aliprantis Antonios, Merck Research Laboratories, Boston, USA;
Allen David, North West Severe Asthma Network, Pennine Acute Hospital NHS Trust, UK
Alving Kjell, Dept Women's & Children's Health, Uppsala University, Uppsala, Sweden
Badorrek P, Fraunhofer ITEM; Hannover, Germany
Balgoma David, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Ballereau S, European institute for Systems Biology and Medicine, University of Lyon, France
Barber Clair, NIHR Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, Southampton, UK;
Batuwitage Manohara Kanangana, Data Science Institute, Imperial College, London, UK
Bautmans An, MSD, Brussels, Belgium
Bedding A, Roche Diagnostics GmbH, Mannheim, Germany
Behndig AF, Umeå University, Umea, Sweden
Beleta Jorge, Almirall S.A., Barcelona, Spain;
Berglind A, MSD, Brussels, Belgium
Berton A, AstraZeneca, Mölndal, Sweden
Bochenek Grazyna, II Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland;
Braun Armin, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany;
Campagna D, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy;
<i>Carayannopoulos Leon, Previously at: MSD, USA;</i>
Casaulta C, University Children's Hospital of Bern, Switzerland
Chaleckis Romanas, Centre of Allergy Research, Karolinska Institutet, Stockholm, Sweden



Davison Timothy Janssen R&D, USA;
De Alba Jorge, Almirall S.A., Barcelona, Spain;
De Lepeleire Inge, MSD, Brussels, BE
Dekker Tamara, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Delin Ingrid, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Dennison P, NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, NIHR-Wellcome Trust Clinical Research Facility, Faculty of Medicine, University of Southampton, Southampton, UK;
Dijkhuis Annemiek, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Dodson Paul, AstraZeneca, Mölndal, Sweden
Draper Aleksandra, BioSci Consulting, Maasmechelen, Belgium;
Dyson K, CROMSOURCE; Stirling, UK
Edwards Jessica, Asthma UK, London, UK;
El Hadjam L, European Institute for Systems Biology and Medicine, University of Lyon
Emma Rosalia, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy;
Ericsson Magnus, Karolinska University Hospital, Stockholm, Sweden
Faulenbach C, Fraunhofer ITEM; Hannover, Germany
Flood Breda, European Federation of Allergy and Airways Diseases Patient's Associations, Brussels, Belgium
Galfy G, Semmelweis University, Budapest, Hungary;
Gallart Hector, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Garissi D, Global Head Clinical Research Division, CROMSOURCE, Italy
Gent J, Royal Brompton and Harefield NHS Foundation Trust, London, UK;
Gerhardsson de Verdier M, AstraZeneca; Mölndal, Sweden;
Gibeon D, National Heart and Lung Institute, Imperial College, London, UK;
Gomez Cristina, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Gove Kerry, NIHR Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, Southampton, UK;
Gozzard Neil, UCB, Slough, UK;
Guillmant-Farry E, Royal Brompton Hospital, London, UK
Henriksson E, Karolinska University Hospital & Karolinska Institutet, Stockholm, Sweden
Hewitt Lorraine, NIHR Southampton Respiratory Biomedical Research Unit, Southampton, UK
Hoda U, Imperial College, London, UK
Hu Richard, Amgen Inc. Thousand Oaks, USA
Hu Sile, National Heart and Lung Institute, Imperial College, London, UK;
Hu X, Amgen Inc.; Thousand Oaks, USA
Jeyasingham E, UK Clinical Operations, GSK, Stockley Park, UK



Johnson K, Centre for respiratory medicine and allergy, Institute of Inflammation and repair, University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK
Jullian N, European Institute for Systems Biology and Medicine, University of Lyon
Kamphuis Juliette, Longfonds, Amersfoort, The Netherlands;
Kennington Erika J., Asthma UK, London, UK;
Kerry Dyson, CromSource, Stirling, UK;
Kerry G, Centre for respiratory medicine and allergy, Institute of Inflammation and repair, University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK
Klüglich M, Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach, Germany
Knobel Hugo, Philips Research Laboratories, Eindhoven, The Netherlands;
Kolmert Johan, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Konradsen J R, Dept. Women's and Children's Health & Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Kots Maxim, Chiesi Pharmaceuticals, SPA, Parma, Italy;
Kretsos Kosmas, UCB, Slough, UK
Krueger L, University Children's Hospital Bern, Switzerland
Kuo Scott, National Heart and Lung Institute, Imperial College, London, UK;
Kupczyk Maciej, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Lambrecht Bart, University of Gent, Gent, Belgium;
Lantz A-S, Karolinska University Hospital & Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Larminie Christopher, GSK, London, UK
Larsson L X, AstraZeneca, Mölndal, Sweden
Latzin P, University Children's Hospital of Bern, Bern, Switzerland
Lazarinis N, Karolinska University Hospital & Karolinska Institutet, Stockholm, Sweden
Lemonnier N, European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France
Lone-Latif Saeeda, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Lowe L A, Centre for respiratory medicine and allergy, Institute of Inflammation and repair, University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK
Manta Alexander, Roche Diagnostics GmbH, Mannheim, Germany
Marouzet Lisa, NIHR Southampton Respiratory Biomedical Research Unit, Southampton, UK
Martin Jane, NIHR Southampton Respiratory Biomedical Research Unit, Southampton, UK
Mathon Caroline, Centre of Allergy Research, Karolinska Institutet, Stockholm, Sweden
McEvoy L, University Hospital, Department of Pulmonary Medicine, Bern, Switzerland
Meah Sally, National Heart and Lung Institute, Imperial College, London, UK;
Menzies-Gow A, Royal Brompton and Harefield NHS Foundation Trust, London, UK;
<i>Metcalf Leanne, Previously at: Asthma UK, London, UK;</i>
Mikus Maria, Science for Life Laboratory & The Royal Institute of Technology, Stockholm,



U-BIOPRED

Sweden;
Monk Philip, Synairgen Research Ltd, Southampton, UK;
Naz Shama, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Nething K, Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach, Germany
Nicholas Ben, University of Southampton, Southampton, UK
Nihlén U, <i>Previously AstraZeneca; Mölndal, Sweden;</i>
Nilsson Peter, Science for Life Laboratory & The Royal Institute of Technology, Stockholm, Sweden;
Niven R, North West Severe Asthma Network, University Hospital South Manchester, UK
Nordlund B, Dept. Women's and Children's Health & Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Nsubuga S, Royal Brompton Hospital, London, UK
Östling Jörgen, AstraZeneca, Mölndal, Sweden;
Pacino Antonio, Lega Italiano Anti Fumo, Catania, Italy;
Palkonen Susanna, European Federation of Allergy and Airways Diseases Patient's Associations, Brussels, Belgium.
Pellet J, European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France
Pennazza Giorgio, Unit of Electronics for Sensor Systems, Department of Engineering, Campus Bio-Medico University of Rome, Rome, Italy
Petrén Anne, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Pink Sandy, NIHR Southampton Respiratory Biomedical Research Unit, Southampton, UK
Pison C, European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France
<i>Rahman-Amin Malayka, Previously at: Asthma UK, London, UK;</i>
Ravanetti Lara, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Ray Emma, NIHR Southampton Respiratory Biomedical Research Unit, Southampton, UK
Reinke Stacey, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
<i>Reynolds Leanne, Previously at: Asthma UK, London, UK;</i>
Riemann K, Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach, Germany
Robberechts Martine, MSD, Brussels, Belgium
Rocha J P, Royal Brompton and Harefield NHS Foundation Trust
Rossios C, National Heart and Lung Institute, Imperial College, London, UK;
Russell Kirsty, National Heart and Lung Institute, Imperial College, London, UK;
Rutgers Michael, Longfonds, Amersfoort, The Netherlands;
Santini G, Università Cattolica del Sacro Cuore, Milan, Italy;
Santonico Marco, Unit of Electronics for Sensor Systems, Department of Engineering, Campus Bio-Medico University of Rome, Rome, Italy
Saqi M, European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon, France



Schoelch Corinna, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
Scott S, North West Severe Asthma Network, Countess of Chester Hospital, UK
Sehgal N, North West Severe Asthma Network; Pennine Acute Hospital NHS Trust
Sjodin Marcus, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Smids Barbara, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Smith Caroline, NIHR Southampton Respiratory Biomedical Research Unit, Southampton, UK
Smith Jessica, Asthma UK, London, UK;
Smith Katherine M., University of Nottingham, UK;
Söderman P, Dept. Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
Sogbesan A, Royal Brompton and Harefield NHS Foundation Trust, London, UK;
Spycher F, University Hospital Department of Pulmonary Medicine, Bern, Switzerland
Staykova Doroteya, University of Southampton, Southampton, UK
Stephan S, Centre for respiratory medicine and allergy, Institute of Inflammation and repair, University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK
Stokholm J, University of Copenhagen and Danish Pediatric Asthma Centre Denmark
Strandberg K, Karolinska University Hospital & Karolinska Institutet, Stockholm, Sweden
Sunther M, Centre for respiratory medicine and allergy, Institute of Inflammation and repair, University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK
Szentkereszty M, Semmelweis University, Budapest, Hungary;
Tamasi L, Semmelweis University, Budapest, Hungary;
Tariq K, NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, NIHR-Wellcome Trust Clinical Research Facility, Faculty of Medicine, University of Southampton, Southampton, UK;
Thörngren John-Olof, Karolinska University Hospital, Stockholm, Sweden
Thorsen Jonathan, COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark;
Valente S, Università Cattolica del Sacro Cuore, Milan, Italy;
van de Pol Marianne, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
van Drunen C M, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Van Eyll Jonathan, UCB, Slough, UK
<i>Versnel Jenny, Previously at: Asthma UK, London, UK;</i>
Vink Anton, Philips Research Laboratories, Eindhoven, The Netherlands;
von Garnier C, University Hospital Bern, Switzerland;
Vyas A, North west Severe Asthma Network, Lancashire Teaching Hospitals NHS Trust, UK
Wald Frans, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
Walker Samantha, Asthma UK, London, UK;
Ward Jonathan, Histochemistry Research Unit, Faculty of Medicine, University of



Southampton, Southampton, UK;
Wetzel Kristiane, Boehringer Ingelheim Pharma GmbH, Biberach, Germany
Wiegman Coen, National Heart and Lung Institute, Imperial College, London, UK;
Williams Siân, International Primary Care Respiratory Group, Aberdeen, Scotland;
Yang Xian, Data Science Institute, Imperial College, London, UK
Yeyasingham Elizabeth, UK Clinical Operations, GSK, Stockley Park, UK;
Yu W, Amgen Inc.; Thousand Oaks, USA
Zetterquist W, Dept. Women's and Children's Health & Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Zolkipli Z, NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK;
Zwinderman A H, Academic Medical Centre, University of Amsterdam, The Netherlands;

<b>Partner organisations</b>	
Novartis Pharma AG	University of Southampton, Southampton, UK
Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands	Imperial College London, London, UK
University of Catania, Catania, Italy	University of Rome 'Tor Vergata', Rome, Italy
Hvidore Hospital, Hvidore, Denmark	Jagiellonian Univ. Medi.College, Krakow, Poland
University Hospital, Inselspital, Bern, Switzerland	Semmelweis University, Budapest, Hungary
University of Manchester, Manchester, UK	Université d'Aix-Marseille, Marseille, France
Fraunhofer Institute, Hannover, Germany	University Hospital, Umea, Sweden
Ghent University, Ghent, Belgium	Ctr. Nat. Recherche Scientifique, Lyon, France
Università Cattolica del Sacro Cuore, Rome, Italy	University Hospital, Copenhagen, Denmark
Karolinska Institutet, Stockholm, Sweden	Nottingham University Hospital, Nottingham, UK
University of Bergen, Bergen, Norway	Netherlands Asthma Foundation, Leusden, NL
European Lung Foundation, Sheffield, UK	Asthma UK, London, UK
European. Fed. of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium	Lega Italiano Anti Fumo, Catania, Italy





U-BIOPRED

International Primary Care Respiratory Group, Aberdeen, Scotland	Philips Research Laboratories, Eindhoven, NL
Synairgen Research Ltd, Southampton, UK	Aerocrine AB, Stockholm, Sweden
BioSci Consulting, Maasmechelen, Belgium	Almirall
AstraZeneca	Boehringer Ingelheim
Chiesi	GlaxoSmithKline
Roche	UCB
Janssen Biologics BV	Amgen NV
Merck Sharp & Dome Corp	

<b>MEMBERS OF THE ETHICS BOARD</b>			
<b>Name</b>	<b>Task</b>	<b>Affiliation</b>	<b>e-mail</b>
Jan-Bas Prins	Biomedical research	LUMC/the Netherlands	J.B.Prins@lumc.nl
Martina Gahlemann	Clinical care	BI/Germany	Martina.Gahlemann@boehringer-ingelheim.com
Luigi Visintin	Legal affairs	LIAF/Italy	visintin@inrete.it
Hazel Evans	Paediatric care	Southampton/UK	hazel.evans@uhs.nhs.uk
Martine Puhl	Patient representation (co chair)	NAF/ the Netherlands	martine@puhl.nl
Lina Buzermaniene	Patient representation	EFA/Lithuania	lina.buzermaniene@pavb.lt
Val Hudson	Patient representation	Asthma UK	hudsonval7@gmail.com
Laura Bond	Patient representation	Asthma UK	lvbond22@googlemail.com
Pim de Boer	Patient representation and pathobiology	IND	deboer.pim@hetnet.nl
Guy Widdershoven	Research ethics	VUMC/the Netherlands	g.widdershoven@vumc.nl
Ralf Sigmund	Research methodology and biostatistics	BI/Germany	ralf.sigmund@boehringer-ingelheim.com



<b>THE PATIENT INPUT PLATFORM</b>	
<b>Name</b>	<b>Country</b>
Amanda Roberts	UK
David Supple (chair)	UK
Dominique Hamerlijnc	The Netherlands
Jenny Negus	UK
Juliëtte Kamphuis	The Netherlands
Lehanne Sergison	UK
Luigi Visintin	Italy
Pim de Boer (co-chair)	The Netherlands
Susanne Onstein	The Netherlands

<b>MEMBERS OF THE SAFETY MONITORING BOARD</b>	
<b>Name</b>	<b>Task</b>
William MacNee	Clinical care
Renato Bernardini	Clinical pharmacology
Louis Bont	Paediatric care and infectious diseases
Per-Ake Wecksell	Patient representation
Pim de Boer	Patient representation and pathobiology (chair)
Martina Gahlemann	Patient safety advice and clinical care (co-chair)
Ralf Sigmund	Bio-informatician